Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 714-720

  Hung, Chao Hung ^a   Hu, Tsung Hui ^a   Lu, Sheng Nan ^a   Kuo, Fang Ying ^a   Chen, Chien Hung ^a   Wang, Jing Houng ^a   Huang, Chao Min ^a   Lee, Chuan Mo ^a   Lin, Chih Yun ^a   Yen, Yi Hao ^a   Chiu, Yi Chun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

diagnosis; dysplastic nodule; hepatitis B virus; hepatocellular carcinoma; microRNAs

Indexed keywords

ALPHA FETOPROTEIN; LET 7B; MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 130B; MICRORNA 15B; MICRORNA 16; MICRORNA 199; MICRORNA 21; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DYSPLASTIC NODULE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER NODULE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; HEPATITIS B; LIVER NEOPLASMS; MIDDLE AGED; PRECANCEROUS CONDITIONS;

AGED; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 84955716160     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29802     Document Type: Article

References (38)

1. Forner A, Llovet JM, Bruix J., Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
2. Chen CJ, Yu MW, Liaw YF., Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S294-S308.
3. Changchien CS, Chen CL, Yen YH, et al., Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 2008; 43: 159-70.
4. Lee WM., Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
5. Chen CJ, Yang HI., Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-38.
6. Schwartz M, Roayaie S, Konstadoulakis M., Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-32.
7. Poon RT, Fan ST., Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10: S39-S45.
8. Bruix J, Sherman M,; Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
9. Collier J, Sherman M., Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
10. Oka H, Tamori A, Kuroki T, et al., Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
11. Hung CH, Chiu YC, Chen CH, et al., MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int 2014; 2014: 486407.
12. Giordano S, Columbano A., MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013; 57: 840-7.
13. Xu J, Wu C, Che X, et al., Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-42.
14. Tomimaru Y, Eguchi H, Nagano H, et al., Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-75.
15. Li J, Wang Y, Yu W, et al., Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70-3.
16. Li LM, Hu ZB, Zhou ZX, et al., Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70: 9798-807.
17. Qi P, Cheng SQ, Wang H, et al., Serum micro-RNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28486.
18. Liu AM, Yao TJ, Wang W, et al., Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2: e000825.
19. Qu KZ, Zhang K, Li H, et al., Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-60.
20. Ma J, Guo R, Wang T, et al., Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3′UTR is associated with fluorouracil resistance of hepatocellular carcinoma. Mol Med Rep 2015; 11: 677-81.
21. Köberle V, Kronenberger B, Pleli T, et al., Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49: 3442-9.
22. Hung CH, Lu SN, Wang JH, et al., Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003; 38: 153-7.
23. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
24. Bihrer V, Friedrich-Rust M, Kronenberger B, et al., Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663-9.
25. Shen Q, Fan J, Yang XR, et al., Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13: 817-26.
26. Mao Y, Yang H, Xu H, et al., Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59: 1687-93.
27. Chang J, Nicolas E, Marks D, et al., miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-13.
28. Morita K, Taketomi A, Shirabe K, et al., Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011; 31: 474-84.
29. Waidmann O, Bihrer V, Pleli T, et al., Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19: e58-e65.
30. Arataki K, Hayes CN, Akamatsu S, et al., Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013; 85: 789-98.
31. Xu J, Zhu X, Wu L, et al., MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int 2012; 32: 752-60.
32. Reinhart BJ, Slack FJ, Basson M, et al., The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901-6.
33. Sempere LF, Christensen M, Silahtaroglu A, et al., Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-20.
34. Joosse SA, Müller V, Steinbach B, et al., Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer 2014; 111: 909-17.
35. Garofalo M, Quintavalle C, Romano G, et al., miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12: 27-33.
36. Pineau P, Volinia S, McJunkin K, et al., miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 264-9.
37. Si ML, Zhu S, Wu H, et al., miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
38. Zhou L, Yang ZX, Song WJ, et al., MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol 2013; 43: 661-9.